scholarly journals Chronic Humoral Rejection: Identification of Antibody-Mediated Chronic Renal Allograft Rejection by C4d Deposits in Peritubular Capillaries

2001 ◽  
Vol 12 (3) ◽  
pp. 574-582 ◽  
Author(s):  
SHAMILA MAUIYYEDI ◽  
PATRICIA DELLA PELLE ◽  
SUSAN SAIDMAN ◽  
A. BERNARD COLLINS ◽  
MANUEL PASCUAL ◽  
...  

Abstract. The pathogenesis of chronic renal allograft rejection (CR) remains obscure. The hypothesis that a subset of CR is mediated by antidonor antibody was tested by determining whether C4d is deposited in peritubular capillaries (PTC) and whether it correlates with circulating antidonor antibodies. All cases (from January 1, 1990, to July 31, 1999) that met histologic criteria for CR and had frozen tissue (28 biopsies, 10 nephrectomies) were included. Controls were renal allograft biopsies with chronic cyclosporine toxicity (n = 21) or nonspecific interstitial fibrosis (n = 10), and native kidneys with end-stage renal disease (n = 10) or chronic interstitial fibrosis (n = 5). Frozen sections were stained by two-color immunofluorescence for C4d, type IV collagen and Ulex europaeus agglutinin I. Antidonor HLA antibody was sought by panel-reactive antibody analysis and/or donor cross matching in sera within 7 wk of biopsy. Overall, 23 of 38 CR cases (61%) had PTC staining for C4d, compared with 1 of 46 (2%) of controls (P < 0.001). C4d in PTC was localized at the interface of endothelium and basement membrane. Most of the C4d-positive CR tested had antidonor HLA antibody (15 of 17; 88%); none of the C4d-negative CR tested (0 of 8) had antidonor antibody (P < 0.0002). The histology of C4d-positive CR was similar to C4d-negative CR, and 1-yr graft survival rates were 62% and 25%, respectively (P = 0.05). Since August 1998, five of six C4d-positive CR cases have been treated with mycophenolate mofetil ± tacrolimus with a 100% 1-yr graft survival, versus 40% before August 1998 (P < 0.03). These data support the hypothesis that a substantial fraction of CR is mediated by antibody (immunologically active). C4d can be used to separate this group of CR from the nonspecific category of chronic allograft nephropathy and may have the potential to guide successful therapeutic intervention.

2019 ◽  
Vol 33 (2) ◽  
pp. 149-160
Author(s):  
Johannes Waiser ◽  
Jens Klotsche ◽  
Nils Lachmann ◽  
Kaiyin Wu ◽  
Birgit Rudolph ◽  
...  

2000 ◽  
Vol 31 (9) ◽  
pp. 1129-1138 ◽  
Author(s):  
Béla Iványi ◽  
Hanan Fahmy ◽  
Holly Brown ◽  
Pál Szenohradszky ◽  
Phil F. Halloran ◽  
...  

2002 ◽  
Vol 61 (4) ◽  
pp. 1516-1526 ◽  
Author(s):  
Mark Haas ◽  
Edward S. Kraus ◽  
Milagros Samaniego-Picota ◽  
Lorraine C. Racusen ◽  
Wen Ni ◽  
...  

2001 ◽  
Vol 33 (1-2) ◽  
pp. 403-404 ◽  
Author(s):  
B.K Book ◽  
P Agrawal ◽  
L.K Dalla Vecchia ◽  
H.M Gebel ◽  
M.D Pescovitz ◽  
...  

2005 ◽  
Vol 79 (2) ◽  
pp. 228-235 ◽  
Author(s):  
Rajiv D. Poduval ◽  
Pradeep V. Kadambi ◽  
Michelle A. Josephson ◽  
Richard A. Cohn ◽  
Robert C. Harland ◽  
...  

2001 ◽  
Vol 12 (11) ◽  
pp. 2482-2489 ◽  
Author(s):  
GEORG A. BÖHMIG ◽  
HEINZ REGELE ◽  
MARKUS EXNER ◽  
VICTOR DERHARTUNIAN ◽  
JOSEF KLETZMAYR ◽  
...  

Abstract. There is increasing evidence for an important pathogenetic role of alloantibodies in acute renal allograft rejection. Acute humoral rejection (AHR) has been reported to be associated with a poor transplant survival. Although treatment modalities for cellular rejection are fairly well established, the optimal treatment for AHR remains undefined. Ten of 352 kidney allograft recipients transplanted at the authors' institution between November 1998 and September 2000 were diagnosed as having AHR, supported by severe graft dysfunction, C4d deposits in peritubular capillaries (PTC), and accumulation of granulocytes in PTC. AHR was diagnosed 18.9 ± 17.5 d posttransplantation. All patients were subjected to immunoadsorption (IA) with protein A (median number of treatment sessions, 9; range, 3 to 17). Seven recipients with additional signs of cellular rejection (according to the Banff classification) received also antithymocyte globulin. In nine of ten patients, AHR was associated with an increase in panel reactive antibody reactivity. A pathogenetic role of alloantibodies was further supported by a positive posttransplant cytotoxic crossmatch in all tested recipients (n= 4). In nine of ten recipients, renal function recovered after initiation of anti-humoral therapy. One patient lost his graft shortly after initiation of specific therapy. Another recipient with partial reversal of AHR returned to dialysis 8 mo after transplantation. Mean serum creatinine in functioning grafts was 2.2 ± 1.2 mg/dl after the last IA session (n= 9) and 1.5 ± 0.5 mg/dl after a follow-up of 14.2 ± 7.1 mo (n= 8). In conclusion, this study suggests that AHR, characterized by severe graft dysfunction, C4d staining, and peritubular granulocytes, can be effectively treated by timely IA. In the majority of patients, IA treatment can restore excellent graft function over a prolonged time period.


1998 ◽  
Vol 138 (3) ◽  
pp. 547-548 ◽  
Author(s):  
Yamazaki ◽  
Yokozeki ◽  
Katayama ◽  
Komai ◽  
Hashimoto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document